November 1st 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
June 30th 2021
FDA approval of teprotumumab as therapeutic offers hope for patients.
April 14th 2021
Sublingual troche sedation represents attractive anesthesia option for specific subset of patients with cataracts.
April 2nd 2021
Study highlights role of demographic and socioeconomic characteristics in treatment.
March 2nd 2021
Autologous serum eye drops and blood products offer hope to patients.